Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence?

G S Hillis, R J Trent, P Winton, A M MacLeod, K P Jennings

    Research output: Contribution to journalArticle

    43 Citations (Scopus)

    Abstract

    The benefits of angiotensin-converting enzyme (ACE) inhibition in the management of cardiac failure have been extensively documented. However, little is known about its impact upon the investigation and management of this condition. We assessed how patients diagnosed as having cardiac failure were investigated, which patients were treated with ACE inhibitors and with what dosages. We reviewed the case notes of all 343 patients discharged from Aberdeen Royal Infirmary 1 July-31 December 1992 with a diagnosis of cardiac failure. In addition, a questionnaire was sent to the general practitioners of the 166 patients still alive in October 1994. Only 40% of patients were discharged from hospital on ACE inhibitors. In 58.8%, the diagnosis of cardiac failure was based purely on clinical or radiological grounds. At discharge, 76.1% of patients were on lower doses of ACE inhibitors than those used in the major survival studies; with 68.9% receiving similar doses two years later. The majority of patients with heart failure are under-investigated and under-treated.
    Original languageEnglish
    Pages (from-to)145-50
    Number of pages6
    JournalQJM
    Volume89
    Issue number2
    Publication statusPublished - 1 Feb 1996

    Fingerprint

    Angiotensin-Converting Enzyme Inhibitors
    Heart Failure
    Peptidyl-Dipeptidase A
    General Practitioners
    Survival

    Keywords

    • Adult
    • Aged
    • Aged, 80 and over
    • Angiotensin-Converting Enzyme Inhibitors
    • Drug Administration Schedule
    • Female
    • Follow-Up Studies
    • Heart Failure
    • Humans
    • Male
    • Middle Aged
    • Patient Discharge
    • Retrospective Studies

    Cite this

    Hillis, G. S., Trent, R. J., Winton, P., MacLeod, A. M., & Jennings, K. P. (1996). Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? QJM, 89(2), 145-50.

    Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? / Hillis, G S; Trent, R J; Winton, P; MacLeod, A M; Jennings, K P.

    In: QJM, Vol. 89, No. 2, 01.02.1996, p. 145-50.

    Research output: Contribution to journalArticle

    Hillis, GS, Trent, RJ, Winton, P, MacLeod, AM & Jennings, KP 1996, 'Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence?', QJM, vol. 89, no. 2, pp. 145-50.
    Hillis GS, Trent RJ, Winton P, MacLeod AM, Jennings KP. Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? QJM. 1996 Feb 1;89(2):145-50.
    Hillis, G S ; Trent, R J ; Winton, P ; MacLeod, A M ; Jennings, K P. / Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence?. In: QJM. 1996 ; Vol. 89, No. 2. pp. 145-50.
    @article{2b1408cc7f3e4cec9fb69757f0131ea4,
    title = "Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence?",
    abstract = "The benefits of angiotensin-converting enzyme (ACE) inhibition in the management of cardiac failure have been extensively documented. However, little is known about its impact upon the investigation and management of this condition. We assessed how patients diagnosed as having cardiac failure were investigated, which patients were treated with ACE inhibitors and with what dosages. We reviewed the case notes of all 343 patients discharged from Aberdeen Royal Infirmary 1 July-31 December 1992 with a diagnosis of cardiac failure. In addition, a questionnaire was sent to the general practitioners of the 166 patients still alive in October 1994. Only 40{\%} of patients were discharged from hospital on ACE inhibitors. In 58.8{\%}, the diagnosis of cardiac failure was based purely on clinical or radiological grounds. At discharge, 76.1{\%} of patients were on lower doses of ACE inhibitors than those used in the major survival studies; with 68.9{\%} receiving similar doses two years later. The majority of patients with heart failure are under-investigated and under-treated.",
    keywords = "Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Drug Administration Schedule, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Patient Discharge, Retrospective Studies",
    author = "Hillis, {G S} and Trent, {R J} and P Winton and MacLeod, {A M} and Jennings, {K P}",
    year = "1996",
    month = "2",
    day = "1",
    language = "English",
    volume = "89",
    pages = "145--50",
    journal = "QJM",
    issn = "1460-2725",
    publisher = "Oxford University Press",
    number = "2",

    }

    TY - JOUR

    T1 - Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence?

    AU - Hillis, G S

    AU - Trent, R J

    AU - Winton, P

    AU - MacLeod, A M

    AU - Jennings, K P

    PY - 1996/2/1

    Y1 - 1996/2/1

    N2 - The benefits of angiotensin-converting enzyme (ACE) inhibition in the management of cardiac failure have been extensively documented. However, little is known about its impact upon the investigation and management of this condition. We assessed how patients diagnosed as having cardiac failure were investigated, which patients were treated with ACE inhibitors and with what dosages. We reviewed the case notes of all 343 patients discharged from Aberdeen Royal Infirmary 1 July-31 December 1992 with a diagnosis of cardiac failure. In addition, a questionnaire was sent to the general practitioners of the 166 patients still alive in October 1994. Only 40% of patients were discharged from hospital on ACE inhibitors. In 58.8%, the diagnosis of cardiac failure was based purely on clinical or radiological grounds. At discharge, 76.1% of patients were on lower doses of ACE inhibitors than those used in the major survival studies; with 68.9% receiving similar doses two years later. The majority of patients with heart failure are under-investigated and under-treated.

    AB - The benefits of angiotensin-converting enzyme (ACE) inhibition in the management of cardiac failure have been extensively documented. However, little is known about its impact upon the investigation and management of this condition. We assessed how patients diagnosed as having cardiac failure were investigated, which patients were treated with ACE inhibitors and with what dosages. We reviewed the case notes of all 343 patients discharged from Aberdeen Royal Infirmary 1 July-31 December 1992 with a diagnosis of cardiac failure. In addition, a questionnaire was sent to the general practitioners of the 166 patients still alive in October 1994. Only 40% of patients were discharged from hospital on ACE inhibitors. In 58.8%, the diagnosis of cardiac failure was based purely on clinical or radiological grounds. At discharge, 76.1% of patients were on lower doses of ACE inhibitors than those used in the major survival studies; with 68.9% receiving similar doses two years later. The majority of patients with heart failure are under-investigated and under-treated.

    KW - Adult

    KW - Aged

    KW - Aged, 80 and over

    KW - Angiotensin-Converting Enzyme Inhibitors

    KW - Drug Administration Schedule

    KW - Female

    KW - Follow-Up Studies

    KW - Heart Failure

    KW - Humans

    KW - Male

    KW - Middle Aged

    KW - Patient Discharge

    KW - Retrospective Studies

    M3 - Article

    C2 - 8729556

    VL - 89

    SP - 145

    EP - 150

    JO - QJM

    JF - QJM

    SN - 1460-2725

    IS - 2

    ER -